(LEAD) SK Biopharm's Q3 operating profit up 66 pct on U.S. sales of seizure drug

Yonhap News Agency · Kang Jae-eun · 2026-11-05 02:11 UTC

SEOUL, Nov. 5 (Yonhap) -- SK Biopharmaceuticals Co., a biopharmaceutical arm of ...

(ATTN: CHANGES headline, lead; RECASTS throughout with more details; ADDS photo)

SEOUL, Nov. 5 (Yonhap) -- SK Biopharmaceuticals Co., a biopharmaceutical arm of SK Group, said Thursday its operating profit rose 65.9 percent from a year earlier, boosted by robust U.S. sales of oral anti-seizure medication.

The company reported an operating profit of 116.3 billion won in the July-September period, according to its regulatory filing.

Read the full story at Yonhap News Agency · All coverage of this story